Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present TRACON Pharmaceuticals, Inc. (NASDAQ: TCON).

Full DD Report for TCON

You must become a subscriber to view this report.


Recent News from (NASDAQ: TCON)

TRACON Pharmaceuticals' (TCON) CEO Charles Theuer on Q1 2018 Results - Earnings Call Transcript
TRACON Pharmaceuticals Inc (TCON) Q1 2018 Earnings Conference Call May 9, 2018 04:30 PM ET Executives Charles Theuer – President and Chief Executive Officer Patricia Bitar – Chief Financial Officer Analysts Chad Messer – Needham & Company Maury Rayc...
Source: SeekingAlpha
Date: May, 09 2018 22:52
Tracon misses by $0.10, beats on revenue
Tracon (NASDAQ: TCON ): Q1 EPS of -$0.46 misses by $0.10 . More news on: Tracon Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 09 2018 16:13
TRACON Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
SAN DIEGO, May 09, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age‐related macular degeneration, today announced financial ...
Source: GlobeNewswire
Date: May, 09 2018 16:05
TRACON to Report First Quarter 2018 Company Highlights and Financial Results on May 9, 2018
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that it will repo...
Source: GlobeNewswire
Date: May, 02 2018 16:05
TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted Wang, Ph.D., of Puissance Capital Management, to Board of Directors
SAN DIEGO, April 09, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced the closing of the pr...
Source: GlobeNewswire
Date: April, 09 2018 08:00
Midday Gainers / Losers (4/2/2018)
Gainers: SLS +167% . SSC +23% . MNOV +21% . ALNA +18% . MARK +15% . BLFS +15% . MBII +14% . CASI +12% . TCON +12% . CHCI +12% . More news on: SELLAS Life Sciences Group, Inc., Seven Stars Cloud Group, Inc., MediciNova, Inc., Stocks on the move, , Read m...
Source: SeekingAlpha
Date: April, 02 2018 12:45
Your Daily Pharma Scoop: Clovis Update, Novartis' MS Results, Vericel's SUMMIT Study
Analysis focus: Clovis Oncology Today we will discuss Clovis Oncology (CLVS), which is up sharply after the obtained a positive opinion from the European Medicines Agency’s ((EMA)) CHMP for Rubraca as a treatment for women with advanced BRCA mutant ovarian cancer with platinum-sensi...
Source: SeekingAlpha
Date: March, 26 2018 08:00
TRACON Pharma secures $38.7M capital raise; shares off 5%
TRACON Pharmaceuticals ( TCON -4.9% ) inks agreements with certain investors for the direct sale of stock and warrants yielding gross proceeds of $38.7M. More news on: Tracon Pharmaceuticals, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: March, 23 2018 10:56
TRACON Pharmaceuticals Announces $38.7 Million Private Placement
SAN DIEGO, March 23, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that it has ent...
Source: GlobeNewswire
Date: March, 23 2018 08:30
TRACON Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
SAN DIEGO, March 21, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that Charles Th...
Source: GlobeNewswire
Date: March, 21 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-172.502.502.552.45101,984
2017-03-104.154.054.154.051,412
2017-03-093.9514.104.153.9029,469
2017-03-083.853.954.003.8536,896
2017-03-074.003.854.003.8043,889

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2118,91367,05728.2044Cover
2018-08-2032,163173,07518.5833Cover
2018-08-173,81825,46714.9920Cover
2018-08-164839,8174.9200Cover
2018-08-154,60332,49614.1648Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TCON.


About TRACON Pharmaceuticals, Inc. (NASDAQ: TCON)

Logo for TRACON Pharmaceuticals, Inc. (NASDAQ: TCON)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: TCON)

      Simplified registration form
      Filing Type: S-3Filing Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 04 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 25 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 25 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 23 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: April, 11 2018
      Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
      Filing Type: DFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 10 2018

       

       


      Daily Technical Chart for (NASDAQ: TCON)

      Daily Technical Chart for (NASDAQ: TCON)


      Stay tuned for daily updates and more on (NASDAQ: TCON)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: TCON)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TCON is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of TCON and does not buy, sell, or trade any shares of TCON. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/